ERBB2 and neoplasm: Bolstering this hypothesis is the observation that the same pDNA vaccine as used in the present trial can efficiently induce Her2-specific antibodies as well as a CD8+ T-cell response and protection from tumor challenge in conventional and human Her2-transgenic BALB/c and HLA-A2 transgenic B6 mice [25,38].